Citi raised the firm’s price target on Exelixis (EXEL) to $56 from $45 and keeps a Buy rating on the shares. The company reported a strong start to the year with total revenue of $555M that easily exceeded consensus by over 12%, the analyst tells investors in a research note. The firm says Exelixis’ follow-on asset zanzalintinib “will have a flurry” of Phase 3 topline readouts in major solid tumor indications in 2025 that could further invigorate sales growth for the company.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXEL:
- Exelixis: Hold Rating Amid Strong Revenue and Uncertain Prospects
- Exelixis price target raised to $44 from $38 at TD Cowen
- Exelixis: Strong Financial Performance and Growth Potential Justify Buy Rating
- Exelixis price target raised to $47 from $40 at Morgan Stanley
- Exelixis price target raised to $38 from $36 at Stifel
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue